Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company. Merck on Thursday said it has secured an ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Germany's Merck KGaA expects annual sales to be at the lower half of its outlook range after third-quarter sales missed expectations. The life-sciences and chemical group said Thursday that it now ...

Prior to joining Alexion in 2015, George was employed by Merck & Co., Inc. for 25 years in IT positions of increasing responsibility. He served as Vice President, Manufacturing and Supply Chain ...

Orna Therapeutics, part of a buzzy cohort of biotech companies established in the wake of the Covid pandemic, has cut more ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...